



MAILING CERTIFICATE

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington D.C. 20231 on January 10, 2001 by Kay Buler Kay Buler
Date Signature (print name)

Handwritten: #8 16/12
Handwritten: Seg. And A
Handwritten: 4/6/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Doherty et al.
Filing Date: February 16, 2000
Serial No.: 09/506,079
For: HER-2 BINDING ANTAGONISTS
Art Unit: 1642
Examiner: J. Hunt
Docket: 49321-16
Date: 10 January 2001

RECEIVED
APR 05 2001
TECH CENTER 1600/2900

Box Non-Fee Amendment
Assistant Commissioner for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the specification (Sequence Listing at pages 34-39) by substituting the enclosed corrected Sequence Listing pages 34-39. The amendments are in response to the NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES, attached to the Office Communication, dated March 15, 2001. No new matter has been added. Entry of the Amendment is respectfully requested.

REMARKS

Applicants now submit (Box SEQUENCE) the appropriate Sequence Listing in paper (C.F.R. 1.821(c)) and computer-readable form (C.F.R. 1.821(e)), along with applicants' statement under (C.F.R. 1.821(f)).

Minor corrections to the Sequence Listing, as originally disclosed in the specification, have been made to bring the Sequence Listing into conformity with the requirements of C.F.R. 1.821-1.825.